Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multitarget ART in primary HIV infection for long-term viral control
2017-000554-19Phase 4Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir, darunavir + cobicistat and tenofovir alafenamide in human immunodeficiency virus infection (HIV) and Seroconversion Syndrome, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Change in total HIV-DNA level. Started Jan 2021; status: completed.
02
Drugs
dolutegravirdarunavir + cobicistattenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)Seroconversion Syndrome
Beyond the preview
Go deeper on 2017-000554-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000554-19.